Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Renal Insufficiency, Chronic | 58 | 2024 | 2255 | 4.130 |
Why?
|
Kidney Failure, Chronic | 33 | 2023 | 2426 | 3.210 |
Why?
|
Renal Dialysis | 18 | 2023 | 1746 | 2.640 |
Why?
|
Diabetic Nephropathies | 16 | 2024 | 979 | 2.480 |
Why?
|
Kidney Transplantation | 19 | 2023 | 4146 | 2.230 |
Why?
|
Glomerular Filtration Rate | 34 | 2024 | 2115 | 1.750 |
Why?
|
Calcinosis | 9 | 2013 | 1478 | 1.670 |
Why?
|
Coronary Artery Disease | 12 | 2022 | 6616 | 1.120 |
Why?
|
Erectile Dysfunction | 4 | 2021 | 453 | 1.040 |
Why?
|
Nephrology | 4 | 2023 | 236 | 0.950 |
Why?
|
Kidney Diseases | 11 | 2023 | 2061 | 0.790 |
Why?
|
Disease Progression | 22 | 2023 | 13427 | 0.680 |
Why?
|
Renal Replacement Therapy | 2 | 2021 | 246 | 0.650 |
Why?
|
Kidney | 17 | 2024 | 7009 | 0.640 |
Why?
|
Albuminuria | 10 | 2023 | 657 | 0.600 |
Why?
|
Cardiovascular Diseases | 22 | 2024 | 15651 | 0.600 |
Why?
|
Diabetes Mellitus, Type 2 | 14 | 2024 | 12200 | 0.590 |
Why?
|
Interleukin-6 | 5 | 2022 | 3203 | 0.570 |
Why?
|
Diabetic Retinopathy | 2 | 2023 | 1258 | 0.560 |
Why?
|
Diabetes Mellitus | 8 | 2022 | 5843 | 0.550 |
Why?
|
Lipoprotein(a) | 3 | 2007 | 494 | 0.490 |
Why?
|
Arteriovenous Shunt, Surgical | 3 | 2017 | 288 | 0.470 |
Why?
|
Fibroblast Growth Factors | 4 | 2016 | 863 | 0.450 |
Why?
|
Coronary Vessels | 4 | 2014 | 3116 | 0.410 |
Why?
|
Health Literacy | 3 | 2014 | 434 | 0.410 |
Why?
|
C-Reactive Protein | 4 | 2021 | 3812 | 0.400 |
Why?
|
Heart Valves | 1 | 2013 | 285 | 0.390 |
Why?
|
Catheters, Indwelling | 2 | 2012 | 427 | 0.380 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2023 | 3399 | 0.370 |
Why?
|
Polytetrafluoroethylene | 1 | 2012 | 245 | 0.370 |
Why?
|
Humans | 132 | 2024 | 755533 | 0.360 |
Why?
|
Graft Survival | 5 | 2023 | 3657 | 0.350 |
Why?
|
Middle Aged | 70 | 2024 | 218055 | 0.350 |
Why?
|
Adult | 60 | 2024 | 217986 | 0.310 |
Why?
|
Allopurinol | 2 | 2020 | 200 | 0.310 |
Why?
|
United States Government Agencies | 1 | 2008 | 26 | 0.310 |
Why?
|
Male | 79 | 2024 | 356577 | 0.310 |
Why?
|
Cohort Studies | 31 | 2022 | 41119 | 0.310 |
Why?
|
Hypertriglyceridemia | 2 | 2003 | 313 | 0.310 |
Why?
|
Kidney Function Tests | 8 | 2024 | 681 | 0.300 |
Why?
|
Prospective Studies | 32 | 2022 | 53991 | 0.300 |
Why?
|
Tunica Intima | 1 | 2009 | 457 | 0.290 |
Why?
|
Renal Insufficiency | 3 | 2023 | 811 | 0.290 |
Why?
|
Minority Health | 1 | 2008 | 80 | 0.280 |
Why?
|
Blood Pressure | 5 | 2021 | 8494 | 0.280 |
Why?
|
Cholesterol, HDL | 3 | 2014 | 1812 | 0.270 |
Why?
|
Female | 74 | 2024 | 387920 | 0.270 |
Why?
|
Aged | 53 | 2024 | 167376 | 0.270 |
Why?
|
Glaucoma | 1 | 2015 | 1175 | 0.260 |
Why?
|
Uric Acid | 3 | 2022 | 797 | 0.260 |
Why?
|
Heart Valve Diseases | 1 | 2013 | 1049 | 0.250 |
Why?
|
Acute Kidney Injury | 3 | 2024 | 1884 | 0.250 |
Why?
|
Aorta | 2 | 2011 | 2037 | 0.250 |
Why?
|
Carotid Stenosis | 1 | 2012 | 862 | 0.250 |
Why?
|
Carotid Arteries | 1 | 2009 | 951 | 0.250 |
Why?
|
Renin-Angiotensin System | 5 | 2020 | 738 | 0.240 |
Why?
|
Cystatin C | 3 | 2023 | 268 | 0.240 |
Why?
|
Health Priorities | 1 | 2008 | 372 | 0.240 |
Why?
|
Atherosclerosis | 4 | 2024 | 3510 | 0.240 |
Why?
|
Proteinuria | 3 | 2019 | 587 | 0.230 |
Why?
|
Heart Failure | 10 | 2024 | 11781 | 0.230 |
Why?
|
Risk Factors | 32 | 2024 | 73860 | 0.230 |
Why?
|
Coronary Disease | 3 | 2014 | 5993 | 0.230 |
Why?
|
Hyperglycemia | 2 | 2022 | 1373 | 0.230 |
Why?
|
Proteomics | 4 | 2024 | 3760 | 0.220 |
Why?
|
Creatinine | 7 | 2024 | 1899 | 0.220 |
Why?
|
Efficiency, Organizational | 1 | 2008 | 689 | 0.220 |
Why?
|
Lipocalins | 2 | 2014 | 161 | 0.210 |
Why?
|
Aortic Diseases | 1 | 2009 | 734 | 0.210 |
Why?
|
United States | 25 | 2023 | 71888 | 0.210 |
Why?
|
Sleep Apnea Syndromes | 1 | 2011 | 973 | 0.210 |
Why?
|
Acute-Phase Proteins | 2 | 2014 | 247 | 0.210 |
Why?
|
Osteopontin | 1 | 2024 | 300 | 0.210 |
Why?
|
Myocardial Infarction | 7 | 2021 | 11871 | 0.210 |
Why?
|
Health Policy | 2 | 2021 | 2664 | 0.200 |
Why?
|
Diet, Sodium-Restricted | 1 | 2024 | 290 | 0.200 |
Why?
|
Resistin | 1 | 2022 | 172 | 0.190 |
Why?
|
Organ Transplantation | 2 | 2003 | 1137 | 0.190 |
Why?
|
Prevalence | 9 | 2020 | 15589 | 0.190 |
Why?
|
Peripheral Arterial Disease | 3 | 2021 | 1300 | 0.190 |
Why?
|
Coronary Stenosis | 1 | 2007 | 819 | 0.180 |
Why?
|
Inflammation | 4 | 2016 | 10717 | 0.180 |
Why?
|
Xanthine Oxidase | 1 | 2020 | 69 | 0.180 |
Why?
|
Adipokines | 1 | 2022 | 311 | 0.170 |
Why?
|
Aspartate Aminotransferases | 1 | 2021 | 414 | 0.170 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2001 | 217 | 0.170 |
Why?
|
Cultural Diversity | 1 | 2023 | 358 | 0.170 |
Why?
|
Insulin Resistance | 1 | 2013 | 3944 | 0.170 |
Why?
|
Kidney Tubules | 2 | 2024 | 449 | 0.160 |
Why?
|
Policy | 1 | 2023 | 510 | 0.160 |
Why?
|
Glomerulonephritis, Membranoproliferative | 1 | 1999 | 39 | 0.160 |
Why?
|
Troponin T | 2 | 2014 | 766 | 0.160 |
Why?
|
Alleles | 2 | 2023 | 6890 | 0.160 |
Why?
|
Regression Analysis | 4 | 2013 | 6364 | 0.160 |
Why?
|
Hypoglycemic Agents | 5 | 2024 | 3118 | 0.160 |
Why?
|
Alanine Transaminase | 1 | 2021 | 605 | 0.160 |
Why?
|
Sodium | 3 | 2022 | 1594 | 0.160 |
Why?
|
Spin Labels | 1 | 2020 | 334 | 0.160 |
Why?
|
Cryoglobulinemia | 1 | 1999 | 84 | 0.160 |
Why?
|
Metformin | 2 | 2024 | 900 | 0.150 |
Why?
|
Hyperlipidemias | 1 | 2003 | 782 | 0.150 |
Why?
|
Cardiomyopathies | 2 | 2024 | 1932 | 0.150 |
Why?
|
Financing, Government | 1 | 2021 | 469 | 0.150 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2010 | 1853 | 0.150 |
Why?
|
Serine Endopeptidases | 1 | 2022 | 1017 | 0.140 |
Why?
|
Research Personnel | 1 | 2021 | 580 | 0.140 |
Why?
|
Research Support as Topic | 1 | 2021 | 699 | 0.140 |
Why?
|
Risk Adjustment | 1 | 2020 | 599 | 0.140 |
Why?
|
Thyroid Diseases | 1 | 2000 | 386 | 0.140 |
Why?
|
Adiponectin | 1 | 2022 | 1113 | 0.130 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12500 | 0.130 |
Why?
|
Obesity, Abdominal | 2 | 2016 | 373 | 0.130 |
Why?
|
Incidence | 8 | 2024 | 21239 | 0.130 |
Why?
|
Single-Cell Analysis | 2 | 2024 | 2329 | 0.130 |
Why?
|
Hematoma | 1 | 2020 | 769 | 0.130 |
Why?
|
Body Mass Index | 5 | 2016 | 12838 | 0.130 |
Why?
|
Hypertrophy, Left Ventricular | 4 | 2015 | 854 | 0.130 |
Why?
|
Obesity | 4 | 2021 | 12843 | 0.130 |
Why?
|
Health Status Disparities | 3 | 2021 | 1806 | 0.120 |
Why?
|
Uromodulin | 1 | 2014 | 44 | 0.120 |
Why?
|
Exercise | 1 | 2011 | 5763 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2010 | 3948 | 0.120 |
Why?
|
Cause of Death | 4 | 2021 | 3707 | 0.120 |
Why?
|
Cross-Sectional Studies | 10 | 2020 | 25696 | 0.120 |
Why?
|
Tissue Donors | 2 | 2023 | 2250 | 0.120 |
Why?
|
Hypertension | 3 | 2024 | 8526 | 0.120 |
Why?
|
N-Acetylgalactosaminyltransferases | 1 | 2014 | 63 | 0.120 |
Why?
|
Hepacivirus | 1 | 2021 | 1334 | 0.120 |
Why?
|
Bicarbonates | 1 | 2015 | 304 | 0.120 |
Why?
|
Leptin | 1 | 2022 | 1595 | 0.120 |
Why?
|
Natriuretic Peptide, Brain | 3 | 2024 | 1696 | 0.110 |
Why?
|
Adiposity | 2 | 2014 | 1846 | 0.110 |
Why?
|
Drug Therapy, Combination | 1 | 2024 | 6481 | 0.110 |
Why?
|
Hepatitis C, Chronic | 1 | 2021 | 1029 | 0.110 |
Why?
|
Patient Preference | 1 | 2020 | 908 | 0.110 |
Why?
|
Fibrinogen | 2 | 2014 | 886 | 0.110 |
Why?
|
Markov Chains | 2 | 2017 | 974 | 0.100 |
Why?
|
Catheterization, Central Venous | 1 | 2017 | 520 | 0.100 |
Why?
|
Lymphoma, B-Cell | 1 | 1999 | 929 | 0.100 |
Why?
|
Chromatin | 1 | 2024 | 2925 | 0.100 |
Why?
|
Young Adult | 15 | 2020 | 58025 | 0.100 |
Why?
|
Hospitalization | 5 | 2020 | 10683 | 0.100 |
Why?
|
Health Care Costs | 2 | 2017 | 3228 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4488 | 0.100 |
Why?
|
Apolipoproteins | 1 | 2013 | 318 | 0.090 |
Why?
|
Potassium | 1 | 2015 | 1318 | 0.090 |
Why?
|
Intra-Abdominal Fat | 1 | 2016 | 606 | 0.090 |
Why?
|
Osteoprotegerin | 1 | 2011 | 175 | 0.090 |
Why?
|
Risk Assessment | 9 | 2024 | 23956 | 0.090 |
Why?
|
Immunosuppressive Agents | 3 | 2010 | 4077 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 6 | 2017 | 15682 | 0.090 |
Why?
|
Waist-Hip Ratio | 1 | 2012 | 515 | 0.090 |
Why?
|
Multivariate Analysis | 6 | 2016 | 12160 | 0.090 |
Why?
|
Quality of Health Care | 2 | 2018 | 4364 | 0.090 |
Why?
|
Pulsatile Flow | 1 | 2011 | 320 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 7 | 2017 | 20404 | 0.090 |
Why?
|
Piperazines | 1 | 2001 | 2506 | 0.090 |
Why?
|
Cadherins | 1 | 2014 | 903 | 0.090 |
Why?
|
Postoperative Complications | 3 | 2008 | 15576 | 0.090 |
Why?
|
Peptide Fragments | 3 | 2024 | 5087 | 0.090 |
Why?
|
Polycystic Kidney Diseases | 1 | 2010 | 133 | 0.090 |
Why?
|
Inflammation Mediators | 2 | 2016 | 1874 | 0.090 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2010 | 231 | 0.080 |
Why?
|
Intraocular Pressure | 1 | 2015 | 1283 | 0.080 |
Why?
|
Pulse | 1 | 2009 | 218 | 0.080 |
Why?
|
Quality-Adjusted Life Years | 2 | 2017 | 1713 | 0.080 |
Why?
|
Cataract | 1 | 2015 | 830 | 0.080 |
Why?
|
Enzyme Inhibitors | 1 | 2020 | 3728 | 0.080 |
Why?
|
Survival Analysis | 3 | 2018 | 10180 | 0.080 |
Why?
|
Acculturation | 1 | 2010 | 174 | 0.080 |
Why?
|
Lipoproteins, HDL | 1 | 2013 | 663 | 0.080 |
Why?
|
Consensus | 3 | 2022 | 3057 | 0.080 |
Why?
|
Smoking | 3 | 2016 | 9047 | 0.080 |
Why?
|
Histocompatibility Testing | 2 | 2008 | 688 | 0.080 |
Why?
|
Membrane Proteins | 2 | 2022 | 7828 | 0.080 |
Why?
|
Health Expenditures | 1 | 2021 | 2343 | 0.080 |
Why?
|
Chromosome Mapping | 1 | 2017 | 4629 | 0.080 |
Why?
|
Graft Occlusion, Vascular | 1 | 2012 | 555 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3341 | 0.080 |
Why?
|
Ankle Brachial Index | 2 | 2021 | 162 | 0.080 |
Why?
|
Time Factors | 8 | 2018 | 39961 | 0.070 |
Why?
|
Sympathetic Nervous System | 1 | 2010 | 516 | 0.070 |
Why?
|
Genetic Loci | 1 | 2017 | 2610 | 0.070 |
Why?
|
DNA Methylation | 1 | 2021 | 4323 | 0.070 |
Why?
|
Comorbidity | 4 | 2017 | 10538 | 0.070 |
Why?
|
Gene Expression Profiling | 1 | 2023 | 9372 | 0.070 |
Why?
|
Fatty Liver | 1 | 2013 | 764 | 0.070 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2017 | 1416 | 0.070 |
Why?
|
Stroke | 3 | 2021 | 9904 | 0.070 |
Why?
|
Morbidity | 1 | 2012 | 1762 | 0.070 |
Why?
|
Tacrolimus | 1 | 2010 | 723 | 0.070 |
Why?
|
Hypolipidemic Agents | 2 | 2003 | 625 | 0.070 |
Why?
|
Lipids | 2 | 2008 | 3333 | 0.070 |
Why?
|
Quality of Life | 3 | 2021 | 13201 | 0.070 |
Why?
|
Statistics as Topic | 1 | 2013 | 2355 | 0.070 |
Why?
|
Postmenopause | 1 | 2016 | 2495 | 0.070 |
Why?
|
Follow-Up Studies | 6 | 2014 | 39179 | 0.070 |
Why?
|
Vasodilation | 1 | 2010 | 963 | 0.070 |
Why?
|
Drug Utilization | 1 | 2012 | 1192 | 0.070 |
Why?
|
HLA-A Antigens | 1 | 2007 | 227 | 0.070 |
Why?
|
Health Promotion | 1 | 2018 | 2208 | 0.070 |
Why?
|
Odds Ratio | 4 | 2021 | 9720 | 0.070 |
Why?
|
Community-Institutional Relations | 1 | 2008 | 207 | 0.070 |
Why?
|
Women's Health | 1 | 2016 | 2053 | 0.070 |
Why?
|
Hemodynamics | 2 | 2020 | 4186 | 0.060 |
Why?
|
Treatment Failure | 2 | 2020 | 2637 | 0.060 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1768 | 0.060 |
Why?
|
Biomedical Research | 1 | 2021 | 3390 | 0.060 |
Why?
|
HLA-B Antigens | 1 | 2007 | 329 | 0.060 |
Why?
|
Pain | 1 | 2020 | 4999 | 0.060 |
Why?
|
Insulin | 1 | 2020 | 6571 | 0.060 |
Why?
|
Prognosis | 6 | 2016 | 29423 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2016 | 17703 | 0.060 |
Why?
|
Triglycerides | 2 | 2014 | 2470 | 0.060 |
Why?
|
HLA-DR Antigens | 1 | 2007 | 629 | 0.060 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 15197 | 0.060 |
Why?
|
Computational Biology | 1 | 2017 | 3502 | 0.060 |
Why?
|
Genotype | 5 | 2022 | 12891 | 0.060 |
Why?
|
Tenascin | 1 | 2024 | 62 | 0.060 |
Why?
|
Mycophenolic Acid | 1 | 2006 | 336 | 0.060 |
Why?
|
Fasting | 1 | 2010 | 1593 | 0.060 |
Why?
|
Genome-Wide Association Study | 7 | 2017 | 12491 | 0.060 |
Why?
|
Dyslipidemias | 1 | 2012 | 892 | 0.060 |
Why?
|
Sex Factors | 4 | 2021 | 10493 | 0.060 |
Why?
|
Holistic Health | 1 | 2024 | 46 | 0.060 |
Why?
|
Calcium | 2 | 2014 | 5706 | 0.060 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2010 | 1016 | 0.060 |
Why?
|
Sleep Deprivation | 1 | 2010 | 834 | 0.060 |
Why?
|
HLA Antigens | 1 | 2008 | 1336 | 0.050 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5496 | 0.050 |
Why?
|
Transplantation, Homologous | 2 | 2008 | 4644 | 0.050 |
Why?
|
Role | 1 | 2003 | 178 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2023 | 12348 | 0.050 |
Why?
|
Case-Control Studies | 4 | 2023 | 21907 | 0.050 |
Why?
|
Amino Acids | 1 | 2008 | 1715 | 0.050 |
Why?
|
Angiopoietins | 1 | 2022 | 85 | 0.050 |
Why?
|
Cathepsin D | 1 | 2022 | 60 | 0.050 |
Why?
|
Angiopoietin-1 | 1 | 2022 | 122 | 0.050 |
Why?
|
Echocardiography | 2 | 2015 | 4957 | 0.050 |
Why?
|
Energy Metabolism | 1 | 2013 | 2858 | 0.050 |
Why?
|
Receptor, TIE-2 | 1 | 2022 | 177 | 0.050 |
Why?
|
Mortality | 3 | 2021 | 2899 | 0.050 |
Why?
|
Myocardium | 1 | 2015 | 4673 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2012 | 2278 | 0.050 |
Why?
|
Educational Status | 1 | 2010 | 2509 | 0.050 |
Why?
|
Vitamin K 1 | 1 | 2022 | 47 | 0.050 |
Why?
|
Primary Health Care | 1 | 2018 | 4633 | 0.050 |
Why?
|
Kidney Tubules, Proximal | 1 | 2024 | 379 | 0.050 |
Why?
|
Iohexol | 1 | 2022 | 195 | 0.050 |
Why?
|
Naphthyridines | 1 | 2022 | 137 | 0.050 |
Why?
|
Logistic Models | 4 | 2021 | 13315 | 0.050 |
Why?
|
Angiopoietin-2 | 1 | 2022 | 171 | 0.050 |
Why?
|
Hemodialysis, Home | 1 | 2021 | 17 | 0.050 |
Why?
|
Treatment Refusal | 1 | 2005 | 427 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2012 | 1983 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2021 | 14383 | 0.050 |
Why?
|
Radial Artery | 1 | 2003 | 197 | 0.050 |
Why?
|
Reoperation | 1 | 2012 | 4283 | 0.050 |
Why?
|
Coronary Angiography | 2 | 2018 | 4554 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2024 | 58549 | 0.050 |
Why?
|
Survival Rate | 2 | 2013 | 12782 | 0.050 |
Why?
|
Health Education | 1 | 2008 | 1050 | 0.050 |
Why?
|
Hypertension, Renal | 1 | 2001 | 139 | 0.050 |
Why?
|
Age Factors | 3 | 2017 | 18366 | 0.050 |
Why?
|
Intermittent Claudication | 1 | 2003 | 307 | 0.050 |
Why?
|
Glucose | 2 | 2022 | 4342 | 0.050 |
Why?
|
Adolescent | 6 | 2020 | 87236 | 0.040 |
Why?
|
Interferon Regulatory Factors | 1 | 2021 | 260 | 0.040 |
Why?
|
Sodium, Dietary | 1 | 2024 | 425 | 0.040 |
Why?
|
Phenotype | 1 | 2018 | 16478 | 0.040 |
Why?
|
Blood Glucose | 2 | 2014 | 6347 | 0.040 |
Why?
|
Treatment Outcome | 5 | 2018 | 64535 | 0.040 |
Why?
|
Hemostasis, Surgical | 1 | 2020 | 130 | 0.040 |
Why?
|
Life Style | 1 | 2011 | 3863 | 0.040 |
Why?
|
Vascular Patency | 1 | 2003 | 903 | 0.040 |
Why?
|
Gene Frequency | 2 | 2017 | 3588 | 0.040 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2022 | 363 | 0.040 |
Why?
|
Health Facilities | 1 | 2005 | 574 | 0.040 |
Why?
|
Albumins | 1 | 2022 | 565 | 0.040 |
Why?
|
Teaching Rounds | 1 | 2024 | 275 | 0.040 |
Why?
|
Cell Count | 1 | 2024 | 1832 | 0.040 |
Why?
|
Protective Agents | 1 | 2020 | 151 | 0.040 |
Why?
|
Nutrition Surveys | 2 | 2018 | 1715 | 0.040 |
Why?
|
Patient Discharge | 1 | 2012 | 3451 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9624 | 0.040 |
Why?
|
Vitamin K | 1 | 2022 | 321 | 0.040 |
Why?
|
Heart Diseases | 1 | 2012 | 2798 | 0.040 |
Why?
|
Hematuria | 1 | 2020 | 233 | 0.040 |
Why?
|
Medicare | 2 | 2021 | 6722 | 0.040 |
Why?
|
Blood Proteins | 1 | 2024 | 1153 | 0.040 |
Why?
|
Glomerular Mesangium | 1 | 1999 | 98 | 0.040 |
Why?
|
Mendelian Randomization Analysis | 1 | 2024 | 977 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2023 | 79686 | 0.040 |
Why?
|
Linear Models | 3 | 2014 | 5863 | 0.040 |
Why?
|
Parathyroid Hormone | 2 | 2017 | 1789 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2010 | 4422 | 0.040 |
Why?
|
Medicaid | 1 | 2012 | 2801 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2012 | 5400 | 0.040 |
Why?
|
Sulfones | 1 | 2001 | 448 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2008 | 4286 | 0.040 |
Why?
|
Models, Biological | 1 | 2014 | 9452 | 0.040 |
Why?
|
Public Health | 2 | 2021 | 2656 | 0.040 |
Why?
|
Education | 1 | 2020 | 537 | 0.040 |
Why?
|
Purines | 1 | 2001 | 602 | 0.040 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2024 | 1523 | 0.040 |
Why?
|
CpG Islands | 1 | 2021 | 1208 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2015 | 3469 | 0.040 |
Why?
|
Anemia | 1 | 2006 | 1503 | 0.040 |
Why?
|
Mood Disorders | 1 | 2003 | 1121 | 0.030 |
Why?
|
Ultrasonography | 1 | 2009 | 5937 | 0.030 |
Why?
|
Cathepsin C | 1 | 2015 | 4 | 0.030 |
Why?
|
Cuba | 1 | 2015 | 47 | 0.030 |
Why?
|
Central America | 1 | 2015 | 64 | 0.030 |
Why?
|
Dominican Republic | 1 | 2015 | 74 | 0.030 |
Why?
|
Interpersonal Relations | 1 | 2003 | 1425 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3407 | 0.030 |
Why?
|
Urinalysis | 1 | 2018 | 367 | 0.030 |
Why?
|
South America | 1 | 2015 | 181 | 0.030 |
Why?
|
Cultural Competency | 1 | 2018 | 292 | 0.030 |
Why?
|
Up-Regulation | 2 | 2016 | 4120 | 0.030 |
Why?
|
Communication Barriers | 1 | 2018 | 412 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7434 | 0.030 |
Why?
|
Informed Consent | 1 | 2021 | 997 | 0.030 |
Why?
|
Sulfotransferases | 1 | 2015 | 149 | 0.030 |
Why?
|
Hypercalcemia | 1 | 2017 | 416 | 0.030 |
Why?
|
Mississippi | 1 | 2014 | 93 | 0.030 |
Why?
|
Puerto Rico | 1 | 2015 | 372 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2023 | 2910 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7782 | 0.030 |
Why?
|
rab GTP-Binding Proteins | 1 | 2015 | 250 | 0.030 |
Why?
|
Delayed Graft Function | 1 | 2014 | 48 | 0.030 |
Why?
|
Trust | 1 | 2018 | 521 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2020 | 1321 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 1999 | 1632 | 0.030 |
Why?
|
Indians, North American | 1 | 2017 | 353 | 0.030 |
Why?
|
Mexico | 1 | 2015 | 747 | 0.030 |
Why?
|
Health Surveys | 1 | 2003 | 4049 | 0.030 |
Why?
|
Models, Economic | 1 | 2017 | 716 | 0.030 |
Why?
|
Genome, Human | 2 | 2017 | 4407 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36042 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2015 | 802 | 0.030 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2014 | 298 | 0.030 |
Why?
|
Research | 1 | 2020 | 1969 | 0.020 |
Why?
|
Diuretics | 1 | 2015 | 611 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2017 | 1267 | 0.020 |
Why?
|
Animals | 5 | 2022 | 167149 | 0.020 |
Why?
|
Hospital Bed Capacity | 1 | 2012 | 207 | 0.020 |
Why?
|
Emotions | 1 | 2003 | 2721 | 0.020 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2011 | 190 | 0.020 |
Why?
|
Serum Albumin | 1 | 2014 | 677 | 0.020 |
Why?
|
Health Status | 1 | 2024 | 4056 | 0.020 |
Why?
|
Life Expectancy | 1 | 2017 | 1248 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2016 | 1719 | 0.020 |
Why?
|
Glucuronidase | 1 | 2011 | 204 | 0.020 |
Why?
|
Carotid Artery, Common | 1 | 2010 | 177 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2022 | 3514 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4043 | 0.020 |
Why?
|
Myocardial Contraction | 1 | 2015 | 1514 | 0.020 |
Why?
|
Electric Impedance | 1 | 2014 | 741 | 0.020 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2015 | 1094 | 0.020 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2011 | 590 | 0.020 |
Why?
|
Living Donors | 1 | 2014 | 630 | 0.020 |
Why?
|
Glucocorticoids | 1 | 1999 | 2148 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 3043 | 0.020 |
Why?
|
Language | 1 | 2018 | 1514 | 0.020 |
Why?
|
Societies, Medical | 1 | 2021 | 3856 | 0.020 |
Why?
|
Mental Health | 1 | 2003 | 3178 | 0.020 |
Why?
|
Myocardial Revascularization | 1 | 2012 | 842 | 0.020 |
Why?
|
Hepatitis C | 1 | 1999 | 1580 | 0.020 |
Why?
|
Phosphates | 1 | 2012 | 765 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2014 | 1163 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2014 | 998 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 2011 | 1489 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2000 | 8555 | 0.020 |
Why?
|
Histocompatibility | 1 | 2008 | 309 | 0.020 |
Why?
|
Rats | 2 | 2015 | 23588 | 0.020 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2007 | 133 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8487 | 0.020 |
Why?
|
Pennsylvania | 1 | 2007 | 613 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2015 | 2820 | 0.020 |
Why?
|
Models, Cardiovascular | 1 | 2011 | 971 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2014 | 1945 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6521 | 0.020 |
Why?
|
Tibia | 1 | 2011 | 1060 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3215 | 0.020 |
Why?
|
Signal Transduction | 2 | 2022 | 23278 | 0.020 |
Why?
|
Patient Selection | 1 | 2017 | 4254 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6884 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3785 | 0.010 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2015 | 2129 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2013 | 19987 | 0.010 |
Why?
|
Poverty | 1 | 2015 | 2662 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6182 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5328 | 0.010 |
Why?
|
Depression | 1 | 2003 | 7961 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 1999 | 12926 | 0.010 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1663 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6237 | 0.010 |
Why?
|
Myocytes, Cardiac | 1 | 2011 | 1646 | 0.010 |
Why?
|
Cadaver | 1 | 2007 | 1342 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4344 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2015 | 3840 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 2007 | 1735 | 0.010 |
Why?
|
Transcription Factors | 1 | 2021 | 12073 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2011 | 6529 | 0.010 |
Why?
|
Mice | 2 | 2022 | 80745 | 0.010 |
Why?
|
Stroke Volume | 1 | 2012 | 5470 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2003 | 1341 | 0.010 |
Why?
|
Bone Density | 1 | 2011 | 3511 | 0.010 |
Why?
|
Heart Ventricles | 1 | 2010 | 3810 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 14636 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 11898 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2005 | 4887 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 9180 | 0.010 |
Why?
|
Registries | 1 | 2012 | 8405 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2011 | 14330 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2013 | 15746 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2011 | 21790 | 0.010 |
Why?
|
DNA | 1 | 2007 | 7225 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2011 | 18027 | 0.010 |
Why?
|
Graft Rejection | 1 | 2005 | 4228 | 0.010 |
Why?
|